Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA filing acceptance for QTORIN 3.9% rapamycin gel, advancing the treatment toward potential U.S. approval.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA filing acceptance for QTORIN 3.9% rapamycin gel, advancing the treatment toward potential U.S. approval
- Priority Review signals FDA consideration of an accelerated review timeline
- PDUFA target action date: February 28, 2027
- Potential regulatory catalyst for Palvella’s microcystic lymphatic malformation program and valuationிழமை
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted QTORIN rapamycin’s NDA and granted Priority Review, establishing a February 28, 2027 PDUFA target date
- Potential first FDA-approved therapy for microcystic lymphatic malformations, addressing more than 30,000 diagnosed U.S. patients
- Phase 3 SELVA met all six prespecified efficacy endpoints with p<0.001; 95% improved on the primary mLM-IGA endpoint
- No drug-related serious adverse events reported; systemic rapamycin concentrations remained below 2 ng/mL
- Standalone U.S. launch targeted for first half of 2027, contingent on approval, marking potential transition to commercial-stage operations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.